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Cardiac Fabry disease with late gadolinium enhancement is a chronic 
inflammatory cardiomyopathy – evidence from multi parametric mapping 
by cardiovascular magnetic resonance 
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Abbreviations 
 
 
FD   Fabry disease 
 
LVH   Left ventricular hypertrophy 
 
CMR   Cardiovascular magnetic resonance 
 
LGE   Late gadolinium enhancement 
 
HCM   Hypertrophic cardiomyopathy 
 
MOLLI  Modified Look-Locker Inversion recovery 
 
cMI   Chronic myocardial infarction 
 
BIFL   Basal inferolateral   
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Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by mutations in α-
galactosidase A. Sphingolipid accumulates in organs including the heart, causing left 
ventricular hypertrophy (LVH) and myocardial fibrosis. Cardiac involvement is the leading 
cause of death in FD. Cardiovascular magnetic resonance (CMR) provides insights with late 
gadolinium enhancement (LGE) characteristically occurring in the basal inferolateral (BIFL) 
wall.1 Histological correlation in advanced disease indicates that this is focal fibrosis, 
although hybrid imaging with PET/MR has suggested this could be inflammation.2 
CMR can now measure three magnetic tissue properties (T1,T2,T2*) and display them as 
color maps. T1 is low in FD due to sphingolipid accumulation.3 However, the link between 
storage and LGE remains obscure. T2 mapping is sensitive to inflammation and edema in 
acute myocardial infarction and myocarditis.4,5 We hypothesized that inflammation 
contributes to LGE in FD, and is measurable using T2 mapping and troponin.  
This is a single centre, single time point study using CMR and blood biomarkers in FD 
(n=47, all gene-positive, males and females) versus hypertrophic cardiomyopathy (HCM; 
n=28, gene-positive, asymmetrical LVH with LGE), chronic myocardial infarction (cMI, 
n=30, 6 months post-reperfused ST-elevation MI) and normal controls (n=60). Ethical 
approval was obtained. All participants underwent CMR, performed at 1.5 Tesla (Avanto, 
Siemens). T1 (MOLLI, 5s(3s)3s sampling) and T2 (WIP 448B, Siemens) mapping were 
acquired on pre-contrast images. Conventional 2D LGE was acquired with phase sensitive 
inversion recovery. High-sensitivity troponin T was measured in FD. 
Seven FD cases did not receive gadolinium due to patient preference. Of the remaining cases, 
18 had LGE (14/21 males – all LVH positive; 4/19 females – 3 LVH positive). All LGE was 
in the BIFL wall, 8 with additional LGE elsewhere. The median LGE extent was 18g (25th 
percentile 12g, 75th percentile 24g).  
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T1 in the remote myocardium in FD was lower than in HCM, cMI and controls (934±61ms 
vs 1021±40ms, 1003±41ms, 1015±36ms; p<0.001). T1 was elevated in LGE areas in all 
diseases but with lesser elevation in FD compared to HCM and cMI (1096±93ms, 
1180±66ms, 1138±52ms; p<0.05). However, the increase over remote T1 was higher in FD 
(204±90ms, 158±62ms, 135±57ms; p<0.05).  
Remote area T2 was normal in all groups (51±3ms, 51±3ms, 48±2ms, controls 49±2ms). 
However, LGE T2 was very high in FD compared to HCM and cMI (64±7ms, 55±4ms, 
54±3ms; p<0.001) and higher than normal in every FD case  (range 55-81ms). The BIFL T2 
was normal in cases without LGE, although slightly higher than controls (51±3ms vs 
49±2ms, p=0.006).  
Of the FD patients, 89%(42/47) had troponin measured, of which 40%(17/42) were elevated 
(median troponin 10ng/L, 25th percentile 1ng/L, 75th percentile 32ng/L, range 3-93ng/L; 
normal reference 0-14ng/L). Troponin elevation only occurred when there was LGE (83% vs 
0%, p<0.001) and was strongly LVH related (94% vs 4%, p<0.001). T2 in the BIFL wall 
correlated with log troponin (rs=0.82, p<0.001) and LV mass (rs=0.69, p<0.001) but not LGE 
extent (rs=0.42, p=0.08). In multivariate analysis, the strongest predictor of troponin was T2 
in the BIFL wall (B=2.4, p<0.001).  
We believe that the best explanation of these results – which combine blood and imaging 
biomarkers – is that LGE in the BIFL wall is not ‘scar’, but inflammation, supporting the 
former PET/MR data. Given that sampling was at a single (random) time point, the 
inflammation would appear chronic, suggesting FD with LGE is not only a storage disease 
but also a chronic inflammatory cardiomyopathy. Inflammation may be the pathological link 
in phenotype development – a concept that opens new avenues of therapy. Both blood 
troponin levels and T2 mapping are potential biomarkers for monitoring candidate therapies 
and risk stratification. We suspect that inflammation plays a wider role in cardiomyopathies, 
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and that T2 and troponin should be further researched in FD and other diseases. Limitations 
of our study include no histological validation, and no additional inflammatory markers.  
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Figure 1A: Mean T2 values in the remote myocardium and LGE area in all groups. 
Error bar = 1 SD. 1B: Corresponding LGE, T1 and T2 map in Fabry disease (FD).  
  
 
